Early diagnosis of advanced liver fibrosis in the compensated stage enables better treatment outcome, leading to fibrosis regression and lower mortality rates from cirrhosis related complications such as HCC and portal hypertension. We used existing NAFLD and FIB-4 scores to initially detect patients with suspected significant liver fibrosis in the general population with no known risk factors. Those patients found to be above a certain threshold, were referred to SWE. Findings demonstrated significant liver fibrosis in patients without known hepatocellular disease, whom were never under a monitoring/treatment program. Early detection is crucial, given the poor outcome and prognosis at the symptomatic/non-compensatory stages of liver fibrosis.
